Literature DB >> 33314351

The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.

Volha Skrahina1, Hanaa Gaber1, Eva-Juliane Vollstedt2, Toni M Förster1, Tatiana Usnich2, Filipa Curado1, Norbert Brüggemann2, Jefri Paul1, Xenia Bogdanovic1, Selen Zülbahar1, Maria Olmedillas1, Snezana Skobalj1, Najim Ameziane1, Peter Bauer1, Ilona Csoti3, Natalia Koleva-Alazeh3, Ulrike Grittner1, Ana Westenberger1, Meike Kasten2, Christian Beetz1, Christine Klein2, Arndt Rolfs1.   

Abstract

BACKGROUND: Genetic stratification of Parkinson's disease (PD) patients facilitates gene-tailored research studies and clinical trials. The objective of this study was to describe the design of and the initial data from the Rostock International Parkinson's Disease (ROPAD) study, an epidemiological observational study aiming to genetically characterize ~10,000 participants.
METHODS: Recruitment criteria included (1) clinical diagnosis of PD, (2) relative of participant with a reportable LRRK2 variant, or (3) North African Berber or Ashkenazi Jew. DNA analysis involved up to 3 successive steps: (1) variant (LRRK2) and gene (GBA) screening, (2) panel sequencing of 68 PD-linked genes, and (3) genome sequencing.
RESULTS: Initial data based on the first 1360 participants indicated that the ROPAD enrollment strategy revealed a genetic diagnostic yield of ~14% among a PD cohort from tertiary referral centers.
CONCLUSIONS: The ROPAD screening protocol is feasible for high-throughput genetic characterization of PD participants and subsequent prioritization for gene-focused research efforts and clinical trials.
© 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  zzm321990GBA; zzm321990LRRK2; Parkinson's disease; genetic factors; observational clinical study

Year:  2020        PMID: 33314351     DOI: 10.1002/mds.28416

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

Review 1.  CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease.

Authors:  Mujeeb Ur Rahman; Muhammad Bilal; Junaid Ali Shah; Ajeet Kaushik; Pierre-Louis Teissedre; Małgorzata Kujawska
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

Review 2.  Psychosis in Parkinson's Disease: A Lesson from Genetics.

Authors:  Efthalia Angelopoulou; Anastasia Bougea; Sokratis G Papageorgiou; Chiara Villa
Journal:  Genes (Basel)       Date:  2022-06-20       Impact factor: 4.141

3.  The commercial genetic testing landscape for Parkinson's disease.

Authors:  Lola Cook; Jeanine Schulze; Jennifer Verbrugge; James C Beck; Karen S Marder; Rachel Saunders-Pullman; Christine Klein; Anna Naito; Roy N Alcalay
Journal:  Parkinsonism Relat Disord       Date:  2021-10-19       Impact factor: 4.891

Review 4.  Genotype-driven therapeutic developments in Parkinson's disease.

Authors:  Jannik Prasuhn; Norbert Brüggemann
Journal:  Mol Med       Date:  2021-04-19       Impact factor: 6.354

5.  Multi-omic landscaping of human midbrains identifies disease-relevant molecular targets and pathways in advanced-stage Parkinson's disease.

Authors:  Lucas Caldi Gomes; Ana Galhoz; Gaurav Jain; Anna-Elisa Roser; Fabian Maass; Eleonora Carboni; Elisabeth Barski; Christof Lenz; Katja Lohmann; Christine Klein; Mathias Bähr; André Fischer; Michael P Menden; Paul Lingor
Journal:  Clin Transl Med       Date:  2022-01

Review 6.  Redefining the hypotheses driving Parkinson's diseases research.

Authors:  Sophie L Farrow; Antony A Cooper; Justin M O'Sullivan
Journal:  NPJ Parkinsons Dis       Date:  2022-04-19

7.  Parkinson disease risks: correctly identifying environmental factors for a chronic disease.

Authors:  Karl Kieburtz; E Ray Dorsey
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

Review 8.  The Genetics of Parkinson's Disease and Implications for Clinical Practice.

Authors:  Jacob Oliver Day; Stephen Mullin
Journal:  Genes (Basel)       Date:  2021-06-30       Impact factor: 4.096

9.  LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort.

Authors:  Tatiana Usnich; Eva-Juliane Vollstedt; Nathalie Schell; Volha Skrahina; Xenia Bogdanovic; Hanaa Gaber; Toni M Förster; Andreas Heuer; Natalia Koleva-Alazeh; Ilona Csoti; Ayse Nazli Basak; Sibel Ertan; Gencer Genc; Peter Bauer; Katja Lohmann; Anne Grünewald; Emma L Schymanski; Joanne Trinh; Susen Schaake; Daniela Berg; Doreen Gruber; Stuart H Isaacson; Andrea A Kühn; Brit Mollenhauer; David J Pedrosa; Kathrin Reetz; Esther M Sammler; Enza Maria Valente; Franco Valzania; Jens Volkmann; Simone Zittel; Norbert Brüggemann; Meike Kasten; Arndt Rolfs; Christine Klein
Journal:  Front Neurol       Date:  2021-08-09       Impact factor: 4.003

Review 10.  Monogenic Parkinson's Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing.

Authors:  Fangzhi Jia; Avi Fellner; Kishore Raj Kumar
Journal:  Genes (Basel)       Date:  2022-03-07       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.